Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history.
Q2 2025 revenue increased between 41% and 42% compared to Q2 2024.
First half of 2025 revenue increased 50-51% vs first half of 2024.
EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the second quarter of 2025 are expected to be in the range of $10.1 to $10.2 million, an increase of 41% to 42% over Q2 2024. This number is within the range of guidance given in the Company’s Q1 2025 earnings release issued on May 9, 2025.
“We’re pleased to once more be on guidance and on track for Q2 and for the first half of 2025,” said CEO Morgan Frank. “As we mentioned last quarter, the first half of 2025 has been a transition period for the company as we have added a new head of sales and now a new head of commercial …